Preclinical Pharmacokinetics and <i>In Vitro</i> Properties of GS-441524, A Potential Oral Drug Candidate for COVID-19 Treatment
Amy Q. Wang(National Institutes of Health), Xin Xu(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Wenwei Huang(National Institutes of Health), Pramod Terse(National Institutes of Health), Mengbi Yang(Chinese University of Hong Kong), Elias Carvalho Padilha(National Institutes of Health), Philip E.J. Sanderson, Catherine Z. Chen(National Institutes of Health), Pranav Shah(Uka Tarsadia University), Natalie R. Hagen(National Institutes of Health)
Cited by 2
Related Papers
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
|ACS Pharmacology & Translational Science|2020|225